Patient Information Leaflet: Information for the User
Azzalure, 125 Units Speywood, Powder for Solution for Injection
(Botulinum Toxin Type A)
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.for you.
Contents of the Pack
Azzalure contains a substance, botulinum toxin type A, that causes muscles to relax. Azzalure acts on the connection between nerves and muscles, blocking the release of a chemical messenger called acetylcholine at the nerve endings. This phenomenon prevents muscle contraction. Muscle relaxation is temporary and gradually recovers.
Some people feel unwell when wrinkles appear on their face. Azzalure can be used in adults under 65 years of age for the temporary improvement of the appearance of glabellar lines (vertical expression lines between the eyebrows) and lateral canthal lines (crow's feet), moderate or severe.
Do not use Azzalure:
Warnings and precautions
Talk to your doctor before starting to use Azzalure:
This information will help your doctor make a decision about the risks and benefits of your treatment.
When you receive treatment with Azzalure, your eyes may become dry. Azzalure can cause your eyes to blink less frequently or produce fewer tears, which could damage the surface of your eyes.
Very rarely, botulinum toxin produces a muscle weakness effect in areas of the body away from the injection site.
When botulinum toxin has been used at more frequent intervals of 12 weeks or at higher doses to treat other conditions, it has been observed very rarely that antibodies are produced. The formation of neutralizing antibodies can reduce the effectiveness of treatment.
If you go to the doctor for any reason, make sure to inform them that you are being treated with Azzalure.
Children and adolescents
Azzalure is not indicated in subjects under 18 years of age.
Using Azzalure with other medicines
Tell your doctor if you are taking, have recently taken, or might take any other medicine, as Azzalure may affect other medicines, especially
Using Azzalure with food and drink
Azzalure injections can be given before or after eating or drinking.
Pregnancy and breastfeeding
You should not use Azzalure during pregnancy. Treatment with Azzalure is not recommended if you are breastfeeding. If you are pregnant or think you may be pregnant or if you are breastfeeding, consult your doctor before using any medicine.
Driving and using machines
You may experience blurred vision, muscle weakness, or temporary generalized weakness after treatment with Azzalure. If this happens, do not drive or use machines.
Azzalure can only be administered by doctors with the appropriate qualification and experience in this treatment and who have the necessary equipment.
Your doctor will prepare and administer the injections. A vial of Azzalure should be used for a single patient and a single treatment session.
The recommended dose of Azzalure is:
The units used in different botulinum toxin products are not the same. The Speywood units of Azzalure are not interchangeable with other botulinum toxin products.
The effect of treatment should be noticeable a few days after injection.
Your doctor will decide on the appropriate interval between each treatment with Azzalure. This interval should not be less than 12 weeks.
Azzalure is not indicated for patients under 18 years of age.
If you use more Azzalure than you should
If you receive more Azzalure than necessary, other muscles different from those treated may begin to weaken. This may not happen immediately. If these symptoms appear, inform your doctor as soon as possible.
In case of overdose or accidental administration, call the Toxicology Information Service, phone: 91 562 04 20 (indicating the medicine and the amount administered).
Like all medicines, Azzalure can cause side effects, although not everybody gets them.
Seek medical attention if:
Tell your doctor if you experience any of these side effects:
For glabellar lines:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Frequency not known (cannot be estimated from the available data)
For lateral canthal lines:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Frequency not known (cannot be estimated from the available data)
Usually, these side effects occur in the first week after injection and do not last long. Usually, they are mild to moderate.
Very rarely, side effects with botulinum toxin have been reported in muscles other than those at the injection site. These effects include excessive muscle weakness, difficulty swallowing, and a feeling of choking when swallowing (if liquids or food enter the airways when trying to swallow, respiratory problems such as pneumonia can occur). If this happens, inform your doctor immediately.
Reporting side effects:
If you experience any side effects, talk to your doctor, even if they are not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep Azzalure out of the sight and reach of children.
Your doctor should not use Azzalure after the expiry date stated on the label. The expiry date is the last day of the month stated.
Store Azzalure in a refrigerator (2°C - 8°C). Do not freeze.
Your doctor will dissolve Azzalure in a liquid solution for injection.
Once reconstituted, it has been shown to have chemical and physical stability for 24 hours between 2-8°C. From a microbiological point of view, unless the reconstitution method excludes the risk of microbial contamination, the medicinal product should be used immediately. In the case that it is not used immediately, the time and conditions of storage after reconstitution are the responsibility of the user.
Composition of Azzalure
*Botulinum toxin type A from Clostridium botulinum(a bacterium) - hemagglutinin complex.
The Speywood units of Azzalure are specific to the product and are not interchangeable with other treatments containing botulinum toxin.
Appearance and pack contents
Azzalure is a powder for solution for injection. The pack is 1 or 2 vials.
Azzalure is a white powder.
Marketing authorisation holder and manufacturer
Marketing authorisation holder:
Ipsen Pharma, S.A.U. Gran Via de les Corts Catalanes 130-136. 08038, Barcelona - Spain
Local representative:
Laboratorios Galderma SA
Serrano Galvache, 56. 28033 Madrid - Spain
Tel: 902 02 75 95
Manufacturer:
Ipsen Manufacturing Ireland Limited
Blanchardstown Industrial Park
Blanchardstown, Dublin 15, Ireland
This leaflet was approved in February 2025.
If you want to obtain more information or are interested in the leaflet in a different format, contact Laboratorios Galderma SA, tel. 902 02 75 95.
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
-----------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Dosage and administration:
See section 3 of the Patient Information Leaflet.
Special precautions for disposal and other handling
Instructions for use, handling, and disposal should be strictly followed.
Reconstitution should be performed in accordance with good practice guidelines, especially respecting aseptic conditions.
Azzalure should be reconstituted with a 9 mg/ml (0.9%) sodium chloride injection solution.
In the dilution table below, the amount of 9 mg/ml (0.9%) sodium chloride injection solution required to be placed in a syringe to obtain a clear and colorless reconstituted solution with the following concentrations is indicated:
Amount of solvent added (sodium chloride 0.9% solution) for a vial of 125 U | Resulting dose |
0.63 ml 1.25 ml | 10 U for 0.05 ml 10 U for 0.1 ml |
To measure exactly 0.63 ml or 1.25 ml, a graduated syringe in increments of 0.1 ml and 0.01 ml will be used.
RECOMMENDATIONS FOR THE DISPOSAL OF CONTAMINATED MATERIALS
Immediately after use and before disposal, the reconstituted Azzalure solution (in the vial or syringe) that has not been used should be inactivated with 2 ml of 0.55% or 1% sodium hypochlorite solution (Dakin's solution).
The vials, syringes, and materials used should not be emptied but should be placed in suitable containers and disposed of according to local procedures.
RECOMMENDATIONS IN CASE OF ACCIDENT DURING HANDLING OF BOTULINUM TOXIN
These instructions for use, handling, and disposal should be strictly followed.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for AZZALURE 125 units SPEYWOOD powder for injectable solution – subject to medical assessment and local rules.